Effect of Mirabegron to Reduce Lower Urinary Tract Symptoms in Prostatitis

ADEEL HYDER ARAIN1, WAQAR AHMED MEMON2, JAVED ALTAF JAT3, TAMOOR JATOI4, AHSAN ALI ARAIN5, POORAN MAL6

1-3Department of Urology, 4Department of Nephrology, Liaquat University of Medical & Health Sciences, Jamshoro
Correspondence to Dr. Javed Altaf Jat, E-mail: javedaltafdr@yahoo.com, Cell: 0333-2888428

ABSTRACT

Aim: To investigate effectiveness and safety of mirabegron in a patient’s symptoms associated with prostatitis in routine practice.

Study Design: Prospective, pilot study

Place and Duration of Study: Department of Urology, Liaquat University Hospital Jamshoro between 1st October 2020 and 30th November 2021

Methodology: Fifteen male subjects in two groups (control and treatment group with Mirabegron), 18 to 50 years old, with acute and chronic prostatitis according to the operational definition were recruited. The overactive bladder started with mirabegron at daily doses of 25mg, 50mg, and 100mg respectively.

Results: The mean ages were 47.7 ± 2.1 years and 33.8 ± 7.0 years respectively in the control and mirabegron groups. The significant efficacy in treating OAB symptoms such as frequent urination, urge incontinence, and urgency. For mirabegron 50mg and 100mg, the mean volume of urine passed per micturition was observed as early as the first assessment after 4-week’s duration and remained stable throughout treatment for up to 12 months. In terms of dry rates, our analyses revealed a considerable improvement with mirabegron 50mg and 100 mg. Patients considered their treatment with mirabegron to be worthwhile, according to an analysis of patient’s satisfaction treatment criteria. Mirabegron observed to be safe in OAB clinical trials with prostatitis that lasted up to 12 months.

Conclusion: When contrasted with existing antimuscarinics that restricted due to associated adverse effects and insufficient effectiveness, mirabegron found improved compliance with balance between effectiveness and safety in Pakistani patients with associated symptoms in prostatitis.

Key words: Prostatitis, Mirabegron, Effectiveness

INTRODUCTION

Globally, prostatitis contributed to the third most common urogenital disease among males which seriously affects the patient’s quality of life. The disease especially affects young and middle-aged males, with common clinical presentations including Frequency, burning/painful micturition or discharge, rectal and lower back pain, fever with chills, loss of libido, and erectile dysfunction. Chronic prostatitis/chronic pelvic pain syndrome accounts for up to 90-95% of all prostatitis cases. For the management of prostatitis, the conventional treatment approach includes antibiotics, antioxidants, and surgery. However, conventional management is less effective and with the complaint of recurrences. Biofeedback, hyperthermia, and magnetic therapy were recently used as physical therapies, but the effectiveness and associated adverse effects are controversial. Presently, the management of prostatitis is still complex and the diagnostic methods are still lacking. The challenges to managing prostatitis are owed to the complexity of the pathogenesis of the prostate disorders. Psychological variables, pathogen infection, sex hormone imbalance, symptoms of the lower urinary tract, inflammation, and aberrant immune response all have an impact on the pathogenesis, with the inflammatory microenvironment reaction being the primary pathogenic mechanism of prostatitis. In the recent era, numerous investigations into the pathogenesis and aetiology of prostatitis have been conducted, and new therapeutic approaches have been identified to increase its effectiveness. The pathology behind the ineffectiveness of traditional pharmacological treatments is because of challenging to access the prostatitis due to its deep placement in the pelvic cavity, the prostate has a unique milieu that is categorized by inflammatory hyperplasia, a decreased pH, bacterial build-up, and a disruption of the blood-prostate barrier.

Clinically, obstructive and irritative voiding symptoms are frequently combined with prostatitis associated with discomfort. Inhibitors of 5-alpha reductase and alpha-1 adrenoceptor antagonists are frequently used salts to treat the blockage of the bladder outflow brought on by prostatitis and prostatic hypertrophy. Unfortunately, the anticholinergic medications demonstrate bothersome diarrhoea, dry mouth, and impaired vision are some of the negative effects. The treatment of lower urinary tract symptoms in patients with BOO associated with prostatitis using the new family of pharmaceutical salt mirabegron, a 3- adrenoceptor agonist, has been studied recently. It has a reduced risk of urine retention and other adverse effects. In addition, mirabegron considerably reduces the frequency of adverse effects such impaired vision, dry mouth, and constipation when compared to conventional anticholinergic medications.

In a patient with OAB and additional lower urinary tract storage symptoms related to prostatitis, the effectiveness and safety of mirabegron were evaluated in routine clinical practice. To investigate the effectiveness and safety of mirabegron in a patient’s symptoms associated with prostatitis in routine practice.

MATERIALS AND METHODS

This prospective, pilot study was conducted at the Urology Department of Liaquat University Hospital Jamshoro between 1st October 2020 and 30th November 2021. A total of 15 male subjects, two groups (control and treatment group with Mirabegron), 18 to 50 years old, with acute and chronic prostatitis according to the operational definition were recruited. The overactive bladder started with mirabegron at daily doses of 25mg, 50mg, and 100mg respectively. Patients with significant bladder diverticulum or urethral stricture, a history of urine retention, clean intermittent catherization, a previous diagnosis of neurogenic bladder, or other disorders were excluded from the study. The data was collected on the design Case Report Form (CRF) as per the criteria and symptoms of prostatitis. The lower urinary tract symptoms were recorded in the designed questionnaire form for analysis. The mean number of micturition episodes per 24 hours was modified from baseline to the conclusion of therapy as the primary outcome. Secondary outcomes included changes in the average amount of urine passed per micturition, the average number of episodes of urgency, nocturia, and urinary incontinence per day, and quality of life indicators. Before the trial started, all baseline laboratory analyses were completed. The fourteen patients on mirabegron were examined alone and with other medications for a period of 1 month to 12 months. The overall OABSS, Qmax, and PVR were recorded. The data was entered and analyzed through SPSS-26. This study was approved by LUMHS Ethical Review Board.
RESULTS
The ages of the participants were 47.7±2.1 and 33.8±7.0 years respectively in control and mirabegron groups. The two groups’ average prostate volumes were 29.51±4.0 mL and 37.38±7.0 mL, respectively. The baseline characteristics were not significantly different. The total International Prostate Symptom Score in control group was reduced from 15.5 to 13.3 (p=0.289) and from 19.7 to 15.5 (p=0.025) in the treatment group after the eight-weeks of therapy with mirabegron. In the median international Prostate Symptom Score storage, 69 (19.4 percent) of the 286 participants were female. Age was 56.29±11.04 on average. The mean quality of life sub-score fell from 3.6 to 3.2 (p=0.053) and 3.7 to 3.3 (p=0.026), respectively, and the symptom sub-scores decrease from 8.4 to 7.8 (p=0.584) and 9.3 to 7.8 (p=0.015) in the control and mirabegron groups. In the control and mirabegron groups, the mean overall Over Active Bladder Symptoms Score decreased from 8.4 to 7.2 (p=0.173) and 8.8 to 7.3 (p=0.005, respectively). In the third quarter, the mean OABSS reduced from 3.6 to 2.9 (p=0.073) and from 3.5 to 2.7 (p=0.002), respectively. In the fourth quarter, the mean OABSS (as measured by the questionnaire) decreased from 2.4 to 2.0 (p=0.306) and from 2.7 to 2.0 (p=0.016) (questions and answers) Mean Qmax increased from 12.9 to 14.2 mL/s (p=0.373) and from 15.3 to 14.9 mL/s (p=0.749) in the control and mirabegron groups, respectively, whereas mean PVR increased from 18.0 to 20.6 mL (p=0.472) and from 23.7 to 42.9 mL (p=0.581) [Table 1].

Table 1: Comparison of mean age, IPSS score, symptoms score, quality of life, OABSS, Q-Max, PVR (control group vs mirabegron)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control Group</th>
<th>Mirabegron Group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>47.7±2.1</td>
<td>33.8±7.0</td>
<td>0.003</td>
</tr>
<tr>
<td>Prostate size (ml)</td>
<td>29.5±14.0</td>
<td>37.3±8.7</td>
<td>0.004</td>
</tr>
<tr>
<td>IPSS reduce after 8 weeks treatment</td>
<td>15.5–13.3</td>
<td>19.7–15.5</td>
<td>0.0298</td>
</tr>
<tr>
<td>Symptoms sub scores decreased after 8 weeks treatment</td>
<td>8.5–7.9</td>
<td>9.1–7.6</td>
<td>0.584</td>
</tr>
<tr>
<td>Mean quality of life sub scores decreased after 8 weeks treatment</td>
<td>3.7–3.1</td>
<td>3.6–3.2</td>
<td>0.452</td>
</tr>
<tr>
<td>Mean QOABSS Q3 decreased after 8 weeks treatment</td>
<td>3.6–2.9</td>
<td>3.5–2.7</td>
<td>0.373</td>
</tr>
<tr>
<td>Mean QOABSS Q4 decreased after 8 weeks treatment</td>
<td>2.4–2.9</td>
<td>3.5–2.7</td>
<td>0.073</td>
</tr>
<tr>
<td>Mean Q-Max decreased after 8 weeks treatment</td>
<td>12.9–14.2</td>
<td>15.3–14.9</td>
<td>0.749</td>
</tr>
<tr>
<td>Mean PVR decreased after 8 weeks treatment</td>
<td>18.0–20.6</td>
<td>23.7–42.9</td>
<td>0.851</td>
</tr>
</tbody>
</table>

Table 2: Comparison of adverse event reported (control group and mirabegron group)

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Control Group</th>
<th>Mirabegron Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal stiffness</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Headache</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

DISCUSSION
The current study investigates the safety and effectiveness of Mirabegron to reduce lower urinary tract symptoms in prostateitis in actual clinical practice in a leading tertiary care hospital in Jamshoro. Mirabegron showed significant effectiveness in treating the exhibiting typical OAB symptoms. International guidelines acknowledge these symptoms as crucial indications of therapy success for OAB.

As early as the first evaluation at week 4, mirabegron at dosages of 50 and 100 mg also showed significant benefits over placebo on important secondary endpoints, and these were maintained throughout the course of treatment. Mirabegron appeared to be well tolerated in OAB clinical trials lasting up to 12 months. As demonstrated in earlier studies examining medications for typical Over-Active-Bladder symptoms, the alteration in placebo was apparent after 7 days therapy, and a maximal benefit was attained and persisted from eight to twelve weeks. At the end of treatment, 50% of the incompetent subjects in each mirabegron therapy group were dry. As a result, mirabegron showed significantly effective in the therapy for OAB indicators. It was found to be equally well tolerated as a placebo and tolterodine, with a minimal frequency of adverse events. The most prevalent and annoying side effect of antimuscarinic therapy is dry mouth.

Therefore, a key advantage of mirabegron therapy may be the low reported of dryness of mouth found with this medication than with tolterodine. A clinically meaningful rise in cardiovascular adverse events was not linked with our investigational drug, which was less apparent than that described in other studies. No patient left the trial due to symptoms linked to greater exposure to these events, and there was no indication that there was a dose-response relationship for them.

CONCLUSION
When contrasted with existing antimuscarinics that restricted due to associated adverse effects and insufficient effectiveness, mirabegron found improved compliance with balance between effectiveness and safety in Pakistani patients with associated symptoms in prostatitis.

REFERENCES
Mirabegron to Reduce Lower Urinary Tract Symptoms


27. Astellas Pharma US Inc. MYRBETRIQ Prescribing Information. September 2012. Available at:https://www.astellas.us/docs/Myrbetrix_WPI.pdf


